New Hybrid Structures Based on Memanthine and Edaravone Molecules

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for Alzheimer's disease.
• Edaravone is a neuroprotective agent that inhibits lipid peroxidation.
• NMDA receptors play a crucial role in excitotoxicity and neurodegenerative diseases.

Purpose of the Study:

• To synthesize novel hybrid molecules integrating memantine and edaravone functionalities.
• To investigate the NMDA receptor blocking properties of these hybrids at both intrachannel and allosteric sites.
• To evaluate the lipid peroxidation inhibitory activity of the synthesized compounds.

Main Methods:

• Chemical synthesis of hybrid molecules linking pyrazolone and adamantane fragments via an alkyl linker.
• Pharmacological evaluation of NMDA receptor antagonism, including intrachannel and allosteric site blockade.
• In vitro assessment of lipid peroxidation inhibition.

Main Results:

• Successful synthesis of novel hybrid structures based on memantine and edaravone.
• The hybrid compounds demonstrated dual-site NMDA receptor blockade (intrachannel and allosteric), a property absent in parent drugs.
• One hybrid compound exhibited significant lipid peroxidation inhibitory activity, comparable to edaravone.

Conclusions:

• The novel hybrid molecules possess dual-site NMDA receptor antagonist properties.
• These hybrids combine the neuroprotective effects of edaravone with enhanced NMDA receptor modulation.
• The most active compound shows promise as a multi-target therapeutic agent for neurodegenerative conditions.